CRLX101: Completed Phase II enrollment

Cerulean completed enrollment of 110 patients in an open-label, international Phase II trial comparing 15 mg/m 2 IV CRLX101 plus IV Avastin on days 1 and 15 of a 28-day cycle vs. standard of care (SOC...